Form 4: Zimmer Biomet Director Arthur J. Higgins Reports Acquisition of Phantom Stock Units

Director Arthur J. Higgins reports acquiring phantom stock units in Zimmer Biomet Holdings, Inc. under the Deferred Compensation Plan for Non-Employee Directors.

Summary

• Arthur J. Higgins, a director at Zimmer Biomet Holdings, Inc., filed a Form 4 on July 2, 2024, reporting a transaction that occurred on June 30, 2024.
• The transaction involved the acquisition of 253.503 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The price of the phantom stock units was $108.48.
• Following the reported transaction, Higgins directly owns 33,036.904 shares of common stock and 253.503 phantom stock units.
• The phantom stock units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to director compensation. The acquisition of phantom stock units can be seen as a slightly positive sign of confidence, but it's not a major event.

Positives

• The acquisition of phantom stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The phantom stock units will be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's participation in a deferred compensation plan, which is a common practice among publicly traded companies.

Comparison to Industry Standards

• Deferred compensation plans for non-employee directors are a common practice in publicly traded companies, including Zimmer Biomet's competitors such as Stryker Corporation (SYK) and Johnson & Johnson (JNJ).
• The structure of the plan, with cash settlement in annual installments after service cessation, is also typical of such arrangements.
• The amount of phantom stock units acquired is relatively small compared to the overall equity holdings of the director.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It provides transparency to shareholders regarding director compensation.

Key Dates